H.C. Wainwright analyst Andres Maldonado resumed coverage of Corbus Pharmaceuticals with a Buy rating and $80 price target. Corbus’ CRB-701 continues to build on the narrative of a best-in-class antibody-drug conjugate, the analyst tells investors in a research note. The firm sees a place for CRB-701 in earlier lines of urothelial cancer treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- B. Riley reiterates Buy on Altimmune, Arrowhead after danuglipron given nod
- Corbus Pharmaceuticals management to meet with B. Riley
- Corbus initiated with Buy on potential in weight loss at B. Riley
- Corbus Pharmaceuticals initiated with a Buy at B. Riley
- Corbus Pharmaceuticals management to meet with Oppenheimer